Additive effects of mGluR
| Autor: | Stephen G, Nuara, Jim C, Gourdon, Shawn, Maddaford, Philippe, Huot |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Dyskinesia Drug-Induced Sulfonamides Indoles Behavior Animal Pyridines Callithrix Receptors Metabotropic Glutamate Piperazines Antiparkinson Agents Levodopa Bridged Bicyclo Compounds Parkinsonian Disorders Psychotic Disorders 1-Methyl-4-phenyl-1 2 3 6-tetrahydropyridine Serotonin 5-HT2 Receptor Antagonists Animals Drug Therapy Combination Female |
| Zdroj: | Naunyn-Schmiedeberg's archives of pharmacology. 394(12) |
| ISSN: | 1432-1912 |
| Popis: | Antagonising serotonin (5-HT) type 2A receptors (5-HTFive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmosets exhibiting dyskinesia and psychosis-like behaviours (PLBs) were administered L-3,4-dihydroxyphenylalanine (L-DOPA) in combination with vehicle or the 5-HTEMD-281,014 reduced dyskinesia and PLBs by up to 47% and 40%, respectively (both P0.001). The addition of LY-354,740, LY-487,379 and LY-354,740/LY-487,379 decreased dyskinesia by 56%, 65% and 77%, while PLBs were diminished by 55%, 63% and 71% (all P0.001). All treatment combinations provided anti-dyskinetic and anti-psychotic benefits significantly greater than those conferred by EMD-281,014 alone (all P0.05). The combination of EMD-281,014/LY-354,740/LY-487,379 resulted in anti-dyskinetic and anti-psychotic effects significantly greater than those conferred by EMD-281,014 with either LY-354,740 or LY-487,379 (both P0.05). No deleterious effects on L-DOPA anti-parkinsonian action were observed.Our results suggest that combining 5-HT |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink